News
Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...
Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer’s disease ...
Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...
Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...
2d
MedPage Today on MSNNovel Anti-Amyloid Drug Aims to Outperform Current StandardsTORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...
Roche has shared new data from its Alzheimer’s disease (AD) development portfolio at this year’s Alzheimer’s Association ...
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...
3d
Free Malaysia Today on MSNRoche to study if new drug can delay or prevent Alzheimer’sThe trial drug Trontinemab is designed to bypass the blood brain barrier, delivering more treatment directly to the brain.
Trontinemab's Phase Ib/IIa Brainshuttle AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining Design of the Phase III TR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results